October 7, 2020 -- The Celiac Disease Foundation has partnered with Provention Bio to provide clinical trial recruitment for the ongoing phase IIB Proactive Celiac Study, which is testing the safety and efficacy of PRV-015, an anti-interleukin-15 monoclonal antibody (mAb).
The study began enrolling patients in August 2020 in the U.S. and plans to recruit patients from Canada later in the year. The foundation will leverage its full suite of patient recruitment services to enroll 220 adults with celiac disease who continue to experience symptoms while following a gluten-free diet.
PRV-015 is designed to block interleukin-15, a cytokine that plays a key role in celiac disease, creating inflammation and intestinal damage. Previous studies have shown that PRV-015 reduces gluten-induced symptoms and markers of intestinal inflammation.
Copyright © 2020 scienceboard.net